Mark G. Kris, MD


May 23, 2013

This feature requires the newest version of Flash. You can download it here.

Hello. I am Mark Kris from Memorial Sloan-Kettering in New York City, speaking to you today in preparation for the Annual Meeting of the American Society of Clinical Oncology (ASCO®).

This year at ASCO, in the area of thoracic cancers, we will see many interesting abstracts presented. My reading of the abstract list so far, however, suggests that this year we will not see a blockbuster trial of any kind. [Thoracic cancer data] are not part of the plenary session, and the information we will get at this ASCO will be more granular and much more focused than in past years.

The thoracic cancer abstracts comprise several themes. One theme is the emergence and greater capabilities of molecular testing. Abstracts about testing will show that testing has become more comprehensive. We will also see the amazing ability of the cancer community to come together and do something that seems to make sense for our patients. For example, we will hear about the experience of the French,[1] where the entire country was mobilized to test each and every patient with non-small cell lung cancer for relevant mutations. This effort was a tour de force and a fantastic example of how a good idea can be put into effect in an amazing way when embraced by, in this case, an entire country. In France, every patient who could benefit from mutation testing receives mutation testing at centers large and small throughout the country.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.